NASDAQ:ANAB 10 January 2026

GSK stock in focus as Jemperli royalty fight escalates ahead of JPM conference

Shares of GSK plc face fresh legal uncertainty on Monday after AnaptysBio moved to dismiss part of a contract claim related to royalties for the cancer drug Jemperli. On Friday, GSK slipped 0.26% to 1,886 pence, just shy of its 52-week peak at 1,909.5. Technical traders are eyeing the 1,830 pence level, close to the 200-day moving average, as a key support zone.

11 January 2026

LSE:GSK·NASDAQ:ANAB·Pharmaceuticals

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

AnaptysBio said it filed a motion asking a U.S. court to dismiss part of a claim by GSK plc’s oncology unit, escalating a dispute over royalties tied to sales of cancer drug Jemperli, a PD-1 inhibitor — a kind of immunotherapy that helps the immune system attack tumours. Tesaro sued AnaptysBio in Delaware in November seeking to terminate a 2014 licence and halve royalty and milestone payments, while AnaptysBio countersued and pointed to trials involving rival PD-1 drugs including Merck’s Keytruda; the case is set for a July 14–17 trial and the court is expected to hear the motion by early March, with royalties under the licence rising to 25% on annual sales above $2.5 billion through patents expiring in 2035-36. GSK did not immediately respond to a request for comment, and its U.S.-listed shares ended Friday up 0.3% at $50.39.

10 January 2026